nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—Cytochrome P450 2D6 Inhibitors—Clobazam—epilepsy syndrome	0.35	0.697	CiPCiCtD
Everolimus—MTOR—epilepsy syndrome	0.215	1	CbGaD
Everolimus—P-Glycoprotein Inhibitors—Zonisamide—epilepsy syndrome	0.152	0.303	CiPCiCtD
Everolimus—CYP3A4—Oxcarbazepine—epilepsy syndrome	0.0113	0.0879	CbGbCtD
Everolimus—CYP3A4—Felbamate—epilepsy syndrome	0.0105	0.0817	CbGbCtD
Everolimus—CYP3A4—Trimethadione—epilepsy syndrome	0.0105	0.0817	CbGbCtD
Everolimus—CYP3A4—Fosphenytoin—epilepsy syndrome	0.00986	0.0768	CbGbCtD
Everolimus—CYP3A4—Clonazepam—epilepsy syndrome	0.00891	0.0694	CbGbCtD
Everolimus—CYP3A4—Clobazam—epilepsy syndrome	0.00855	0.0666	CbGbCtD
Everolimus—CYP3A4—Rufinamide—epilepsy syndrome	0.00727	0.0566	CbGbCtD
Everolimus—CYP3A4—Carbamazepine—epilepsy syndrome	0.00708	0.0552	CbGbCtD
Everolimus—CYP3A4—Primidone—epilepsy syndrome	0.00661	0.0515	CbGbCtD
Everolimus—CYP3A4—Phenytoin—epilepsy syndrome	0.00635	0.0495	CbGbCtD
Everolimus—CYP3A4—Propofol—epilepsy syndrome	0.00592	0.0462	CbGbCtD
Everolimus—CYP3A4—Acetazolamide—epilepsy syndrome	0.00566	0.0441	CbGbCtD
Everolimus—CYP3A4—Phenobarbital—epilepsy syndrome	0.00566	0.0441	CbGbCtD
Everolimus—CYP3A4—Midazolam—epilepsy syndrome	0.00558	0.0435	CbGbCtD
Everolimus—CYP3A4—Diazepam—epilepsy syndrome	0.00537	0.0418	CbGbCtD
Everolimus—CYP3A4—Zonisamide—epilepsy syndrome	0.00524	0.0408	CbGbCtD
Everolimus—CYP3A4—Valproic Acid—epilepsy syndrome	0.00423	0.033	CbGbCtD
Everolimus—CYP3A4—Topiramate—epilepsy syndrome	0.00382	0.0297	CbGbCtD
Everolimus—MTOR—forelimb—epilepsy syndrome	0.00332	0.238	CbGeAlD
Everolimus—MTOR—hindbrain—epilepsy syndrome	0.00136	0.0975	CbGeAlD
Everolimus—MTOR—brainstem—epilepsy syndrome	0.000779	0.0559	CbGeAlD
Everolimus—MTOR—forebrain—epilepsy syndrome	0.000751	0.0539	CbGeAlD
Everolimus—MTOR—telencephalon—epilepsy syndrome	0.000691	0.0496	CbGeAlD
Everolimus—FKBP1A—forebrain—epilepsy syndrome	0.000676	0.0485	CbGeAlD
Everolimus—FKBP1A—telencephalon—epilepsy syndrome	0.000621	0.0446	CbGeAlD
Everolimus—Pimecrolimus—MTOR—epilepsy syndrome	0.000532	0.239	CrCbGaD
Everolimus—FKBP1A—medulla oblongata—epilepsy syndrome	0.000488	0.035	CbGeAlD
Everolimus—MTOR—spinal cord—epilepsy syndrome	0.000484	0.0347	CbGeAlD
Everolimus—FKBP1A—midbrain—epilepsy syndrome	0.000446	0.032	CbGeAlD
Everolimus—FKBP1A—spinal cord—epilepsy syndrome	0.000435	0.0312	CbGeAlD
Everolimus—MTOR—head—epilepsy syndrome	0.00043	0.0309	CbGeAlD
Everolimus—MTOR—nervous system—epilepsy syndrome	0.000408	0.0293	CbGeAlD
Everolimus—MTOR—central nervous system—epilepsy syndrome	0.000393	0.0282	CbGeAlD
Everolimus—Sirolimus—FGF2—epilepsy syndrome	0.000388	0.174	CrCbGaD
Everolimus—FKBP1A—head—epilepsy syndrome	0.000387	0.0278	CbGeAlD
Everolimus—MTOR—cerebellum—epilepsy syndrome	0.000384	0.0275	CbGeAlD
Everolimus—FKBP1A—nervous system—epilepsy syndrome	0.000367	0.0263	CbGeAlD
Everolimus—Temsirolimus—MTOR—epilepsy syndrome	0.000359	0.161	CrCbGaD
Everolimus—FKBP1A—central nervous system—epilepsy syndrome	0.000353	0.0253	CbGeAlD
Everolimus—FKBP1A—cerebellum—epilepsy syndrome	0.000345	0.0248	CbGeAlD
Everolimus—Tacrolimus—MTOR—epilepsy syndrome	0.000316	0.142	CrCbGaD
Everolimus—Sirolimus—MTOR—epilepsy syndrome	0.000316	0.142	CrCbGaD
Everolimus—MTOR—brain—epilepsy syndrome	0.000312	0.0224	CbGeAlD
Everolimus—FKBP1A—brain—epilepsy syndrome	0.00028	0.0201	CbGeAlD
Everolimus—CYP3A4—nervous system—epilepsy syndrome	0.00012	0.0086	CbGeAlD
Everolimus—CYP3A4—central nervous system—epilepsy syndrome	0.000115	0.00828	CbGeAlD
Everolimus—Temsirolimus—CYP2D6—epilepsy syndrome	8.65e-05	0.0389	CrCbGaD
Everolimus—Temsirolimus—ABCB1—epilepsy syndrome	6.17e-05	0.0278	CrCbGaD
Everolimus—Tacrolimus—ALB—epilepsy syndrome	5.7e-05	0.0256	CrCbGaD
Everolimus—Sirolimus—ABCB1—epilepsy syndrome	5.44e-05	0.0244	CrCbGaD
Everolimus—Tacrolimus—ABCB1—epilepsy syndrome	5.44e-05	0.0244	CrCbGaD
Everolimus—Anorexia—Valproic Acid—epilepsy syndrome	1.52e-05	0.000155	CcSEcCtD
Everolimus—Tremor—Gabapentin—epilepsy syndrome	1.52e-05	0.000154	CcSEcCtD
Everolimus—Rash—Diazepam—epilepsy syndrome	1.51e-05	0.000154	CcSEcCtD
Everolimus—Dermatitis—Diazepam—epilepsy syndrome	1.51e-05	0.000154	CcSEcCtD
Everolimus—Arthralgia—Pregabalin—epilepsy syndrome	1.5e-05	0.000153	CcSEcCtD
Everolimus—Myalgia—Pregabalin—epilepsy syndrome	1.5e-05	0.000153	CcSEcCtD
Everolimus—Chest pain—Pregabalin—epilepsy syndrome	1.5e-05	0.000153	CcSEcCtD
Everolimus—Ill-defined disorder—Gabapentin—epilepsy syndrome	1.5e-05	0.000153	CcSEcCtD
Everolimus—Dizziness—Zonisamide—epilepsy syndrome	1.5e-05	0.000153	CcSEcCtD
Everolimus—Headache—Diazepam—epilepsy syndrome	1.5e-05	0.000153	CcSEcCtD
Everolimus—Anxiety—Pregabalin—epilepsy syndrome	1.5e-05	0.000152	CcSEcCtD
Everolimus—Diarrhoea—Clonazepam—epilepsy syndrome	1.5e-05	0.000152	CcSEcCtD
Everolimus—Anaemia—Gabapentin—epilepsy syndrome	1.5e-05	0.000152	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	1.49e-05	0.000152	CcSEcCtD
Everolimus—Hypotension—Valproic Acid—epilepsy syndrome	1.49e-05	0.000152	CcSEcCtD
Everolimus—Asthenia—Carbamazepine—epilepsy syndrome	1.49e-05	0.000152	CcSEcCtD
Everolimus—Agitation—Gabapentin—epilepsy syndrome	1.49e-05	0.000151	CcSEcCtD
Everolimus—Diarrhoea—Phenytoin—epilepsy syndrome	1.49e-05	0.000151	CcSEcCtD
Everolimus—Discomfort—Pregabalin—epilepsy syndrome	1.49e-05	0.000151	CcSEcCtD
Everolimus—Nausea—Fosphenytoin—epilepsy syndrome	1.49e-05	0.000151	CcSEcCtD
Everolimus—Diarrhoea—Oxcarbazepine—epilepsy syndrome	1.48e-05	0.000151	CcSEcCtD
Everolimus—Angioedema—Gabapentin—epilepsy syndrome	1.48e-05	0.000151	CcSEcCtD
Everolimus—Hypersensitivity—Lamotrigine—epilepsy syndrome	1.48e-05	0.00015	CcSEcCtD
Everolimus—Vomiting—Felbamate—epilepsy syndrome	1.48e-05	0.00015	CcSEcCtD
Everolimus—Dry mouth—Pregabalin—epilepsy syndrome	1.47e-05	0.00015	CcSEcCtD
Everolimus—Pruritus—Carbamazepine—epilepsy syndrome	1.47e-05	0.000149	CcSEcCtD
Everolimus—Rash—Felbamate—epilepsy syndrome	1.46e-05	0.000149	CcSEcCtD
Everolimus—Eye disorder—Topiramate—epilepsy syndrome	1.46e-05	0.000149	CcSEcCtD
Everolimus—Dermatitis—Felbamate—epilepsy syndrome	1.46e-05	0.000149	CcSEcCtD
Everolimus—Malaise—Gabapentin—epilepsy syndrome	1.46e-05	0.000149	CcSEcCtD
Everolimus—Headache—Felbamate—epilepsy syndrome	1.45e-05	0.000148	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Valproic Acid—epilepsy syndrome	1.45e-05	0.000148	CcSEcCtD
Everolimus—Cardiac disorder—Topiramate—epilepsy syndrome	1.45e-05	0.000148	CcSEcCtD
Everolimus—Flushing—Topiramate—epilepsy syndrome	1.45e-05	0.000148	CcSEcCtD
Everolimus—Syncope—Gabapentin—epilepsy syndrome	1.45e-05	0.000148	CcSEcCtD
Everolimus—Leukopenia—Gabapentin—epilepsy syndrome	1.45e-05	0.000147	CcSEcCtD
Everolimus—Dizziness—Clonazepam—epilepsy syndrome	1.45e-05	0.000147	CcSEcCtD
Everolimus—Nausea—Vigabatrin—epilepsy syndrome	1.45e-05	0.000147	CcSEcCtD
Everolimus—Vomiting—Zonisamide—epilepsy syndrome	1.45e-05	0.000147	CcSEcCtD
Everolimus—Insomnia—Valproic Acid—epilepsy syndrome	1.44e-05	0.000147	CcSEcCtD
Everolimus—Oedema—Pregabalin—epilepsy syndrome	1.44e-05	0.000147	CcSEcCtD
Everolimus—Asthenia—Lamotrigine—epilepsy syndrome	1.44e-05	0.000146	CcSEcCtD
Everolimus—Dizziness—Phenytoin—epilepsy syndrome	1.44e-05	0.000146	CcSEcCtD
Everolimus—Rash—Zonisamide—epilepsy syndrome	1.43e-05	0.000146	CcSEcCtD
Everolimus—Infection—Pregabalin—epilepsy syndrome	1.43e-05	0.000146	CcSEcCtD
Everolimus—Paraesthesia—Valproic Acid—epilepsy syndrome	1.43e-05	0.000146	CcSEcCtD
Everolimus—Palpitations—Gabapentin—epilepsy syndrome	1.43e-05	0.000146	CcSEcCtD
Everolimus—Dermatitis—Zonisamide—epilepsy syndrome	1.43e-05	0.000146	CcSEcCtD
Everolimus—Dizziness—Oxcarbazepine—epilepsy syndrome	1.43e-05	0.000146	CcSEcCtD
Everolimus—Nausea—Diazepam—epilepsy syndrome	1.43e-05	0.000145	CcSEcCtD
Everolimus—Loss of consciousness—Gabapentin—epilepsy syndrome	1.42e-05	0.000145	CcSEcCtD
Everolimus—Headache—Zonisamide—epilepsy syndrome	1.42e-05	0.000145	CcSEcCtD
Everolimus—Dyspnoea—Valproic Acid—epilepsy syndrome	1.42e-05	0.000145	CcSEcCtD
Everolimus—Diarrhoea—Carbamazepine—epilepsy syndrome	1.42e-05	0.000145	CcSEcCtD
Everolimus—Angiopathy—Topiramate—epilepsy syndrome	1.42e-05	0.000144	CcSEcCtD
Everolimus—Pruritus—Lamotrigine—epilepsy syndrome	1.42e-05	0.000144	CcSEcCtD
Everolimus—Shock—Pregabalin—epilepsy syndrome	1.42e-05	0.000144	CcSEcCtD
Everolimus—Somnolence—Valproic Acid—epilepsy syndrome	1.42e-05	0.000144	CcSEcCtD
Everolimus—Immune system disorder—Topiramate—epilepsy syndrome	1.41e-05	0.000144	CcSEcCtD
Everolimus—Nervous system disorder—Pregabalin—epilepsy syndrome	1.41e-05	0.000144	CcSEcCtD
Everolimus—Cough—Gabapentin—epilepsy syndrome	1.41e-05	0.000144	CcSEcCtD
Everolimus—Thrombocytopenia—Pregabalin—epilepsy syndrome	1.41e-05	0.000144	CcSEcCtD
Everolimus—Mediastinal disorder—Topiramate—epilepsy syndrome	1.41e-05	0.000144	CcSEcCtD
Everolimus—Tachycardia—Pregabalin—epilepsy syndrome	1.41e-05	0.000143	CcSEcCtD
Everolimus—Chills—Topiramate—epilepsy syndrome	1.41e-05	0.000143	CcSEcCtD
Everolimus—Dyspepsia—Valproic Acid—epilepsy syndrome	1.4e-05	0.000143	CcSEcCtD
Everolimus—Convulsion—Gabapentin—epilepsy syndrome	1.4e-05	0.000143	CcSEcCtD
Everolimus—Skin disorder—Pregabalin—epilepsy syndrome	1.4e-05	0.000142	CcSEcCtD
Everolimus—Hypertension—Gabapentin—epilepsy syndrome	1.4e-05	0.000142	CcSEcCtD
Everolimus—Hyperhidrosis—Pregabalin—epilepsy syndrome	1.39e-05	0.000142	CcSEcCtD
Everolimus—Vomiting—Clonazepam—epilepsy syndrome	1.39e-05	0.000142	CcSEcCtD
Everolimus—Decreased appetite—Valproic Acid—epilepsy syndrome	1.39e-05	0.000141	CcSEcCtD
Everolimus—Alopecia—Topiramate—epilepsy syndrome	1.38e-05	0.000141	CcSEcCtD
Everolimus—Vomiting—Phenytoin—epilepsy syndrome	1.38e-05	0.000141	CcSEcCtD
Everolimus—Rash—Clonazepam—epilepsy syndrome	1.38e-05	0.00014	CcSEcCtD
Everolimus—Dermatitis—Clonazepam—epilepsy syndrome	1.38e-05	0.00014	CcSEcCtD
Everolimus—Myalgia—Gabapentin—epilepsy syndrome	1.38e-05	0.00014	CcSEcCtD
Everolimus—Chest pain—Gabapentin—epilepsy syndrome	1.38e-05	0.00014	CcSEcCtD
Everolimus—Arthralgia—Gabapentin—epilepsy syndrome	1.38e-05	0.00014	CcSEcCtD
Everolimus—Nausea—Felbamate—epilepsy syndrome	1.38e-05	0.00014	CcSEcCtD
Everolimus—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	1.38e-05	0.00014	CcSEcCtD
Everolimus—Vomiting—Oxcarbazepine—epilepsy syndrome	1.38e-05	0.00014	CcSEcCtD
Everolimus—Fatigue—Valproic Acid—epilepsy syndrome	1.38e-05	0.00014	CcSEcCtD
Everolimus—Anxiety—Gabapentin—epilepsy syndrome	1.37e-05	0.00014	CcSEcCtD
Everolimus—Anorexia—Pregabalin—epilepsy syndrome	1.37e-05	0.00014	CcSEcCtD
Everolimus—Dizziness—Carbamazepine—epilepsy syndrome	1.37e-05	0.00014	CcSEcCtD
Everolimus—Diarrhoea—Lamotrigine—epilepsy syndrome	1.37e-05	0.00014	CcSEcCtD
Everolimus—Headache—Clonazepam—epilepsy syndrome	1.37e-05	0.00014	CcSEcCtD
Everolimus—Rash—Phenytoin—epilepsy syndrome	1.37e-05	0.00014	CcSEcCtD
Everolimus—Mental disorder—Topiramate—epilepsy syndrome	1.37e-05	0.00014	CcSEcCtD
Everolimus—Dermatitis—Phenytoin—epilepsy syndrome	1.37e-05	0.000139	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	1.37e-05	0.000139	CcSEcCtD
Everolimus—Rash—Oxcarbazepine—epilepsy syndrome	1.36e-05	0.000139	CcSEcCtD
Everolimus—Constipation—Valproic Acid—epilepsy syndrome	1.36e-05	0.000139	CcSEcCtD
Everolimus—Pain—Valproic Acid—epilepsy syndrome	1.36e-05	0.000139	CcSEcCtD
Everolimus—Dermatitis—Oxcarbazepine—epilepsy syndrome	1.36e-05	0.000139	CcSEcCtD
Everolimus—Headache—Phenytoin—epilepsy syndrome	1.36e-05	0.000139	CcSEcCtD
Everolimus—Erythema—Topiramate—epilepsy syndrome	1.36e-05	0.000139	CcSEcCtD
Everolimus—Malnutrition—Topiramate—epilepsy syndrome	1.36e-05	0.000139	CcSEcCtD
Everolimus—Discomfort—Gabapentin—epilepsy syndrome	1.36e-05	0.000139	CcSEcCtD
Everolimus—Headache—Oxcarbazepine—epilepsy syndrome	1.36e-05	0.000138	CcSEcCtD
Everolimus—Nausea—Zonisamide—epilepsy syndrome	1.35e-05	0.000137	CcSEcCtD
Everolimus—Dry mouth—Gabapentin—epilepsy syndrome	1.35e-05	0.000137	CcSEcCtD
Everolimus—Hypotension—Pregabalin—epilepsy syndrome	1.35e-05	0.000137	CcSEcCtD
Everolimus—Flatulence—Topiramate—epilepsy syndrome	1.34e-05	0.000137	CcSEcCtD
Everolimus—Dysgeusia—Topiramate—epilepsy syndrome	1.33e-05	0.000136	CcSEcCtD
Everolimus—Dizziness—Lamotrigine—epilepsy syndrome	1.33e-05	0.000135	CcSEcCtD
Everolimus—Oedema—Gabapentin—epilepsy syndrome	1.32e-05	0.000134	CcSEcCtD
Everolimus—Vomiting—Carbamazepine—epilepsy syndrome	1.32e-05	0.000134	CcSEcCtD
Everolimus—Back pain—Topiramate—epilepsy syndrome	1.32e-05	0.000134	CcSEcCtD
Everolimus—Feeling abnormal—Valproic Acid—epilepsy syndrome	1.31e-05	0.000134	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Pregabalin—epilepsy syndrome	1.31e-05	0.000134	CcSEcCtD
Everolimus—Infection—Gabapentin—epilepsy syndrome	1.31e-05	0.000134	CcSEcCtD
Everolimus—Muscle spasms—Topiramate—epilepsy syndrome	1.31e-05	0.000133	CcSEcCtD
Everolimus—Rash—Carbamazepine—epilepsy syndrome	1.31e-05	0.000133	CcSEcCtD
Everolimus—Dermatitis—Carbamazepine—epilepsy syndrome	1.31e-05	0.000133	CcSEcCtD
Everolimus—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	1.3e-05	0.000133	CcSEcCtD
Everolimus—Insomnia—Pregabalin—epilepsy syndrome	1.3e-05	0.000133	CcSEcCtD
Everolimus—Nausea—Clonazepam—epilepsy syndrome	1.3e-05	0.000132	CcSEcCtD
Everolimus—Headache—Carbamazepine—epilepsy syndrome	1.3e-05	0.000132	CcSEcCtD
Everolimus—Shock—Gabapentin—epilepsy syndrome	1.3e-05	0.000132	CcSEcCtD
Everolimus—Nervous system disorder—Gabapentin—epilepsy syndrome	1.3e-05	0.000132	CcSEcCtD
Everolimus—Paraesthesia—Pregabalin—epilepsy syndrome	1.29e-05	0.000132	CcSEcCtD
Everolimus—Thrombocytopenia—Gabapentin—epilepsy syndrome	1.29e-05	0.000132	CcSEcCtD
Everolimus—Nausea—Phenytoin—epilepsy syndrome	1.29e-05	0.000131	CcSEcCtD
Everolimus—Tachycardia—Gabapentin—epilepsy syndrome	1.29e-05	0.000131	CcSEcCtD
Everolimus—Dyspnoea—Pregabalin—epilepsy syndrome	1.29e-05	0.000131	CcSEcCtD
Everolimus—Nausea—Oxcarbazepine—epilepsy syndrome	1.29e-05	0.000131	CcSEcCtD
Everolimus—Vision blurred—Topiramate—epilepsy syndrome	1.28e-05	0.000131	CcSEcCtD
Everolimus—Skin disorder—Gabapentin—epilepsy syndrome	1.28e-05	0.000131	CcSEcCtD
Everolimus—Somnolence—Pregabalin—epilepsy syndrome	1.28e-05	0.00013	CcSEcCtD
Everolimus—Hyperhidrosis—Gabapentin—epilepsy syndrome	1.28e-05	0.00013	CcSEcCtD
Everolimus—Tremor—Topiramate—epilepsy syndrome	1.28e-05	0.00013	CcSEcCtD
Everolimus—Vomiting—Lamotrigine—epilepsy syndrome	1.28e-05	0.00013	CcSEcCtD
Everolimus—Rash—Lamotrigine—epilepsy syndrome	1.27e-05	0.000129	CcSEcCtD
Everolimus—Ill-defined disorder—Topiramate—epilepsy syndrome	1.26e-05	0.000129	CcSEcCtD
Everolimus—Dermatitis—Lamotrigine—epilepsy syndrome	1.26e-05	0.000129	CcSEcCtD
Everolimus—Abdominal pain—Valproic Acid—epilepsy syndrome	1.26e-05	0.000128	CcSEcCtD
Everolimus—Body temperature increased—Valproic Acid—epilepsy syndrome	1.26e-05	0.000128	CcSEcCtD
Everolimus—Anorexia—Gabapentin—epilepsy syndrome	1.26e-05	0.000128	CcSEcCtD
Everolimus—Anaemia—Topiramate—epilepsy syndrome	1.26e-05	0.000128	CcSEcCtD
Everolimus—Headache—Lamotrigine—epilepsy syndrome	1.26e-05	0.000128	CcSEcCtD
Everolimus—Decreased appetite—Pregabalin—epilepsy syndrome	1.25e-05	0.000127	CcSEcCtD
Everolimus—Agitation—Topiramate—epilepsy syndrome	1.25e-05	0.000127	CcSEcCtD
Everolimus—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	1.25e-05	0.000127	CcSEcCtD
Everolimus—Fatigue—Pregabalin—epilepsy syndrome	1.24e-05	0.000126	CcSEcCtD
Everolimus—Hypotension—Gabapentin—epilepsy syndrome	1.24e-05	0.000126	CcSEcCtD
Everolimus—Nausea—Carbamazepine—epilepsy syndrome	1.23e-05	0.000125	CcSEcCtD
Everolimus—Pain—Pregabalin—epilepsy syndrome	1.23e-05	0.000125	CcSEcCtD
Everolimus—Constipation—Pregabalin—epilepsy syndrome	1.23e-05	0.000125	CcSEcCtD
Everolimus—Malaise—Topiramate—epilepsy syndrome	1.23e-05	0.000125	CcSEcCtD
Everolimus—Syncope—Topiramate—epilepsy syndrome	1.22e-05	0.000124	CcSEcCtD
Everolimus—Leukopenia—Topiramate—epilepsy syndrome	1.22e-05	0.000124	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Gabapentin—epilepsy syndrome	1.2e-05	0.000123	CcSEcCtD
Everolimus—Palpitations—Topiramate—epilepsy syndrome	1.2e-05	0.000123	CcSEcCtD
Everolimus—Loss of consciousness—Topiramate—epilepsy syndrome	1.2e-05	0.000122	CcSEcCtD
Everolimus—Insomnia—Gabapentin—epilepsy syndrome	1.2e-05	0.000122	CcSEcCtD
Everolimus—Nausea—Lamotrigine—epilepsy syndrome	1.19e-05	0.000121	CcSEcCtD
Everolimus—Cough—Topiramate—epilepsy syndrome	1.19e-05	0.000121	CcSEcCtD
Everolimus—Feeling abnormal—Pregabalin—epilepsy syndrome	1.19e-05	0.000121	CcSEcCtD
Everolimus—Paraesthesia—Gabapentin—epilepsy syndrome	1.19e-05	0.000121	CcSEcCtD
Everolimus—Convulsion—Topiramate—epilepsy syndrome	1.18e-05	0.00012	CcSEcCtD
Everolimus—Gastrointestinal pain—Pregabalin—epilepsy syndrome	1.18e-05	0.00012	CcSEcCtD
Everolimus—Dyspnoea—Gabapentin—epilepsy syndrome	1.18e-05	0.00012	CcSEcCtD
Everolimus—Hypertension—Topiramate—epilepsy syndrome	1.18e-05	0.00012	CcSEcCtD
Everolimus—Somnolence—Gabapentin—epilepsy syndrome	1.18e-05	0.00012	CcSEcCtD
Everolimus—Hypersensitivity—Valproic Acid—epilepsy syndrome	1.18e-05	0.00012	CcSEcCtD
Everolimus—Dyspepsia—Gabapentin—epilepsy syndrome	1.16e-05	0.000118	CcSEcCtD
Everolimus—Chest pain—Topiramate—epilepsy syndrome	1.16e-05	0.000118	CcSEcCtD
Everolimus—Myalgia—Topiramate—epilepsy syndrome	1.16e-05	0.000118	CcSEcCtD
Everolimus—Arthralgia—Topiramate—epilepsy syndrome	1.16e-05	0.000118	CcSEcCtD
Everolimus—Anxiety—Topiramate—epilepsy syndrome	1.16e-05	0.000118	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	1.15e-05	0.000117	CcSEcCtD
Everolimus—Decreased appetite—Gabapentin—epilepsy syndrome	1.15e-05	0.000117	CcSEcCtD
Everolimus—Discomfort—Topiramate—epilepsy syndrome	1.15e-05	0.000117	CcSEcCtD
Everolimus—Asthenia—Valproic Acid—epilepsy syndrome	1.14e-05	0.000116	CcSEcCtD
Everolimus—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	1.14e-05	0.000116	CcSEcCtD
Everolimus—Fatigue—Gabapentin—epilepsy syndrome	1.14e-05	0.000116	CcSEcCtD
Everolimus—Abdominal pain—Pregabalin—epilepsy syndrome	1.14e-05	0.000116	CcSEcCtD
Everolimus—Body temperature increased—Pregabalin—epilepsy syndrome	1.14e-05	0.000116	CcSEcCtD
Everolimus—Dry mouth—Topiramate—epilepsy syndrome	1.13e-05	0.000115	CcSEcCtD
Everolimus—Constipation—Gabapentin—epilepsy syndrome	1.13e-05	0.000115	CcSEcCtD
Everolimus—Pain—Gabapentin—epilepsy syndrome	1.13e-05	0.000115	CcSEcCtD
Everolimus—Pruritus—Valproic Acid—epilepsy syndrome	1.13e-05	0.000115	CcSEcCtD
Everolimus—Oedema—Topiramate—epilepsy syndrome	1.11e-05	0.000113	CcSEcCtD
Everolimus—Infection—Topiramate—epilepsy syndrome	1.11e-05	0.000112	CcSEcCtD
Everolimus—Shock—Topiramate—epilepsy syndrome	1.09e-05	0.000111	CcSEcCtD
Everolimus—Diarrhoea—Valproic Acid—epilepsy syndrome	1.09e-05	0.000111	CcSEcCtD
Everolimus—Nervous system disorder—Topiramate—epilepsy syndrome	1.09e-05	0.000111	CcSEcCtD
Everolimus—Feeling abnormal—Gabapentin—epilepsy syndrome	1.09e-05	0.000111	CcSEcCtD
Everolimus—Thrombocytopenia—Topiramate—epilepsy syndrome	1.09e-05	0.000111	CcSEcCtD
Everolimus—Tachycardia—Topiramate—epilepsy syndrome	1.09e-05	0.00011	CcSEcCtD
Everolimus—Gastrointestinal pain—Gabapentin—epilepsy syndrome	1.08e-05	0.00011	CcSEcCtD
Everolimus—Skin disorder—Topiramate—epilepsy syndrome	1.08e-05	0.00011	CcSEcCtD
Everolimus—Hyperhidrosis—Topiramate—epilepsy syndrome	1.08e-05	0.000109	CcSEcCtD
Everolimus—Hypersensitivity—Pregabalin—epilepsy syndrome	1.06e-05	0.000108	CcSEcCtD
Everolimus—Anorexia—Topiramate—epilepsy syndrome	1.06e-05	0.000108	CcSEcCtD
Everolimus—Dizziness—Valproic Acid—epilepsy syndrome	1.05e-05	0.000107	CcSEcCtD
Everolimus—Body temperature increased—Gabapentin—epilepsy syndrome	1.05e-05	0.000106	CcSEcCtD
Everolimus—Abdominal pain—Gabapentin—epilepsy syndrome	1.05e-05	0.000106	CcSEcCtD
Everolimus—Hypotension—Topiramate—epilepsy syndrome	1.04e-05	0.000106	CcSEcCtD
Everolimus—Asthenia—Pregabalin—epilepsy syndrome	1.03e-05	0.000105	CcSEcCtD
Everolimus—Pruritus—Pregabalin—epilepsy syndrome	1.02e-05	0.000104	CcSEcCtD
Everolimus—Vomiting—Valproic Acid—epilepsy syndrome	1.01e-05	0.000103	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Topiramate—epilepsy syndrome	1.01e-05	0.000103	CcSEcCtD
Everolimus—Insomnia—Topiramate—epilepsy syndrome	1.01e-05	0.000102	CcSEcCtD
Everolimus—Rash—Valproic Acid—epilepsy syndrome	1.01e-05	0.000102	CcSEcCtD
Everolimus—Dermatitis—Valproic Acid—epilepsy syndrome	1e-05	0.000102	CcSEcCtD
Everolimus—Headache—Valproic Acid—epilepsy syndrome	9.99e-06	0.000102	CcSEcCtD
Everolimus—Paraesthesia—Topiramate—epilepsy syndrome	9.99e-06	0.000102	CcSEcCtD
Everolimus—Dyspnoea—Topiramate—epilepsy syndrome	9.92e-06	0.000101	CcSEcCtD
Everolimus—Somnolence—Topiramate—epilepsy syndrome	9.89e-06	0.000101	CcSEcCtD
Everolimus—Diarrhoea—Pregabalin—epilepsy syndrome	9.87e-06	0.0001	CcSEcCtD
Everolimus—Dyspepsia—Topiramate—epilepsy syndrome	9.79e-06	9.96e-05	CcSEcCtD
Everolimus—Hypersensitivity—Gabapentin—epilepsy syndrome	9.74e-06	9.91e-05	CcSEcCtD
Everolimus—Decreased appetite—Topiramate—epilepsy syndrome	9.67e-06	9.83e-05	CcSEcCtD
Everolimus—Gastrointestinal disorder—Topiramate—epilepsy syndrome	9.6e-06	9.77e-05	CcSEcCtD
Everolimus—Fatigue—Topiramate—epilepsy syndrome	9.59e-06	9.75e-05	CcSEcCtD
Everolimus—Dizziness—Pregabalin—epilepsy syndrome	9.54e-06	9.7e-05	CcSEcCtD
Everolimus—Pain—Topiramate—epilepsy syndrome	9.51e-06	9.67e-05	CcSEcCtD
Everolimus—Constipation—Topiramate—epilepsy syndrome	9.51e-06	9.67e-05	CcSEcCtD
Everolimus—Asthenia—Gabapentin—epilepsy syndrome	9.49e-06	9.65e-05	CcSEcCtD
Everolimus—Nausea—Valproic Acid—epilepsy syndrome	9.47e-06	9.64e-05	CcSEcCtD
Everolimus—Pruritus—Gabapentin—epilepsy syndrome	9.36e-06	9.51e-05	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—VEGFA—epilepsy syndrome	9.24e-06	0.00023	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—AKT1—epilepsy syndrome	9.21e-06	0.000229	CbGpPWpGaD
Everolimus—Vomiting—Pregabalin—epilepsy syndrome	9.17e-06	9.32e-05	CcSEcCtD
Everolimus—Feeling abnormal—Topiramate—epilepsy syndrome	9.17e-06	9.32e-05	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB4—AKT1—epilepsy syndrome	9.17e-06	0.000228	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HBEGF—epilepsy syndrome	9.14e-06	0.000227	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CHRM1—epilepsy syndrome	9.13e-06	0.000227	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PDYN—epilepsy syndrome	9.13e-06	0.000227	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GRM1—epilepsy syndrome	9.13e-06	0.000227	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCR7—epilepsy syndrome	9.13e-06	0.000227	CbGpPWpGaD
Everolimus—Gastrointestinal pain—Topiramate—epilepsy syndrome	9.1e-06	9.25e-05	CcSEcCtD
Everolimus—MTOR—Immune System—CCR2—epilepsy syndrome	9.1e-06	0.000226	CbGpPWpGaD
Everolimus—Rash—Pregabalin—epilepsy syndrome	9.09e-06	9.25e-05	CcSEcCtD
Everolimus—Dermatitis—Pregabalin—epilepsy syndrome	9.08e-06	9.24e-05	CcSEcCtD
Everolimus—MTOR—Immune System—IL1RN—epilepsy syndrome	9.06e-06	0.000225	CbGpPWpGaD
Everolimus—Diarrhoea—Gabapentin—epilepsy syndrome	9.05e-06	9.2e-05	CcSEcCtD
Everolimus—Headache—Pregabalin—epilepsy syndrome	9.03e-06	9.19e-05	CcSEcCtD
Everolimus—MTOR—Immune System—DUSP6—epilepsy syndrome	9.02e-06	0.000224	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—TSC2—epilepsy syndrome	8.98e-06	0.000223	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AKT3—epilepsy syndrome	8.97e-06	0.000223	CbGpPWpGaD
Everolimus—FKBP1A—Disease—TSC2—epilepsy syndrome	8.95e-06	0.000222	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—SRC—epilepsy syndrome	8.9e-06	0.000221	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—AKT1—epilepsy syndrome	8.8e-06	0.000219	CbGpPWpGaD
Everolimus—Body temperature increased—Topiramate—epilepsy syndrome	8.79e-06	8.94e-05	CcSEcCtD
Everolimus—Abdominal pain—Topiramate—epilepsy syndrome	8.79e-06	8.94e-05	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—ADAM10—epilepsy syndrome	8.76e-06	0.000218	CbGpPWpGaD
Everolimus—FKBP1A—Disease—APOE—epilepsy syndrome	8.75e-06	0.000218	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—AKT1—epilepsy syndrome	8.75e-06	0.000218	CbGpPWpGaD
Everolimus—Dizziness—Gabapentin—epilepsy syndrome	8.74e-06	8.89e-05	CcSEcCtD
Everolimus—MTOR—Signaling by FGFR—AKT1—epilepsy syndrome	8.71e-06	0.000217	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—AKT1—epilepsy syndrome	8.71e-06	0.000217	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—AKT1—epilepsy syndrome	8.67e-06	0.000216	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—AKT1—epilepsy syndrome	8.63e-06	0.000215	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IL6ST—epilepsy syndrome	8.6e-06	0.000214	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GAL—epilepsy syndrome	8.58e-06	0.000213	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GFAP—epilepsy syndrome	8.58e-06	0.000213	CbGpPWpGaD
Everolimus—Nausea—Pregabalin—epilepsy syndrome	8.57e-06	8.71e-05	CcSEcCtD
Everolimus—CYP3A4—Metabolism—CA13—epilepsy syndrome	8.55e-06	0.000213	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—epilepsy syndrome	8.5e-06	0.000211	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CASP2—epilepsy syndrome	8.48e-06	0.000211	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CHRM3—epilepsy syndrome	8.48e-06	0.000211	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GRM5—epilepsy syndrome	8.48e-06	0.000211	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD40—epilepsy syndrome	8.46e-06	0.00021	CbGpPWpGaD
Everolimus—Vomiting—Gabapentin—epilepsy syndrome	8.41e-06	8.55e-05	CcSEcCtD
Everolimus—Rash—Gabapentin—epilepsy syndrome	8.34e-06	8.48e-05	CcSEcCtD
Everolimus—Dermatitis—Gabapentin—epilepsy syndrome	8.33e-06	8.47e-05	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—PRKCB—epilepsy syndrome	8.29e-06	0.000206	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—S100B—epilepsy syndrome	8.29e-06	0.000206	CbGpPWpGaD
Everolimus—Headache—Gabapentin—epilepsy syndrome	8.28e-06	8.42e-05	CcSEcCtD
Everolimus—FKBP1A—Disease—IL6ST—epilepsy syndrome	8.22e-06	0.000204	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SOCS3—epilepsy syndrome	8.21e-06	0.000204	CbGpPWpGaD
Everolimus—Hypersensitivity—Topiramate—epilepsy syndrome	8.2e-06	8.34e-05	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—CDC42—epilepsy syndrome	8.19e-06	0.000204	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NOS2—epilepsy syndrome	8.16e-06	0.000203	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CX3CR1—epilepsy syndrome	8.13e-06	0.000202	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—AKT1—epilepsy syndrome	8.11e-06	0.000202	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—epilepsy syndrome	8.11e-06	0.000202	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—AKT1—epilepsy syndrome	8.11e-06	0.000202	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—AKT1—epilepsy syndrome	8.04e-06	0.0002	CbGpPWpGaD
Everolimus—Asthenia—Topiramate—epilepsy syndrome	7.98e-06	8.12e-05	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—CHRM2—epilepsy syndrome	7.98e-06	0.000198	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—BDKRB1—epilepsy syndrome	7.98e-06	0.000198	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CX3CL1—epilepsy syndrome	7.98e-06	0.000198	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—AKT1—epilepsy syndrome	7.97e-06	0.000198	CbGpPWpGaD
Everolimus—MTOR—Immune System—HBEGF—epilepsy syndrome	7.95e-06	0.000198	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—AKT1—epilepsy syndrome	7.94e-06	0.000197	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AVP—epilepsy syndrome	7.92e-06	0.000197	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—FOS—epilepsy syndrome	7.88e-06	0.000196	CbGpPWpGaD
Everolimus—Pruritus—Topiramate—epilepsy syndrome	7.87e-06	8e-05	CcSEcCtD
Everolimus—Nausea—Gabapentin—epilepsy syndrome	7.85e-06	7.99e-05	CcSEcCtD
Everolimus—MTOR—Disease—SLC2A1—epilepsy syndrome	7.81e-06	0.000194	CbGpPWpGaD
Everolimus—MTOR—Immune System—AKT3—epilepsy syndrome	7.8e-06	0.000194	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GABBR1—epilepsy syndrome	7.76e-06	0.000193	CbGpPWpGaD
Everolimus—MTOR—Disease—JUNB—epilepsy syndrome	7.75e-06	0.000193	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CASP8—epilepsy syndrome	7.7e-06	0.000191	CbGpPWpGaD
Everolimus—MTOR—Disease—NOS1—epilepsy syndrome	7.69e-06	0.000191	CbGpPWpGaD
Everolimus—Diarrhoea—Topiramate—epilepsy syndrome	7.61e-06	7.74e-05	CcSEcCtD
Everolimus—MTOR—B Cell Activation—AKT1—epilepsy syndrome	7.51e-06	0.000187	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HES1—epilepsy syndrome	7.49e-06	0.000186	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HRH3—epilepsy syndrome	7.44e-06	0.000185	CbGpPWpGaD
Everolimus—Dizziness—Topiramate—epilepsy syndrome	7.36e-06	7.48e-05	CcSEcCtD
Everolimus—MTOR—Disease—HBEGF—epilepsy syndrome	7.34e-06	0.000183	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—OPRM1—epilepsy syndrome	7.32e-06	0.000182	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—FYN—epilepsy syndrome	7.29e-06	0.000181	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—H2AFX—epilepsy syndrome	7.26e-06	0.000181	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MEF2C—epilepsy syndrome	7.25e-06	0.00018	CbGpPWpGaD
Everolimus—MTOR—Immune System—S100B—epilepsy syndrome	7.21e-06	0.000179	CbGpPWpGaD
Everolimus—MTOR—Disease—AKT3—epilepsy syndrome	7.21e-06	0.000179	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—epilepsy syndrome	7.19e-06	0.000179	CbGpPWpGaD
Everolimus—MTOR—Immune System—SOCS3—epilepsy syndrome	7.14e-06	0.000178	CbGpPWpGaD
Everolimus—MTOR—Immune System—CDC42—epilepsy syndrome	7.12e-06	0.000177	CbGpPWpGaD
Everolimus—Vomiting—Topiramate—epilepsy syndrome	7.07e-06	7.19e-05	CcSEcCtD
Everolimus—MTOR—Disease—ADAM10—epilepsy syndrome	7.04e-06	0.000175	CbGpPWpGaD
Everolimus—Rash—Topiramate—epilepsy syndrome	7.01e-06	7.13e-05	CcSEcCtD
Everolimus—Dermatitis—Topiramate—epilepsy syndrome	7.01e-06	7.13e-05	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—YWHAZ—epilepsy syndrome	7.01e-06	0.000174	CbGpPWpGaD
Everolimus—Headache—Topiramate—epilepsy syndrome	6.97e-06	7.09e-05	CcSEcCtD
Everolimus—MTOR—Innate Immune System—FGF2—epilepsy syndrome	6.95e-06	0.000173	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NGF—epilepsy syndrome	6.93e-06	0.000172	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCR3—epilepsy syndrome	6.92e-06	0.000172	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NPY—epilepsy syndrome	6.74e-06	0.000168	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ATP2A2—epilepsy syndrome	6.74e-06	0.000168	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCR5—epilepsy syndrome	6.74e-06	0.000168	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—FGF2—epilepsy syndrome	6.68e-06	0.000166	CbGpPWpGaD
Everolimus—FKBP1A—Disease—FGF2—epilepsy syndrome	6.65e-06	0.000165	CbGpPWpGaD
Everolimus—Nausea—Topiramate—epilepsy syndrome	6.61e-06	6.72e-05	CcSEcCtD
Everolimus—MTOR—Innate Immune System—BCL2—epilepsy syndrome	6.6e-06	0.000164	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HTR2A—epilepsy syndrome	6.59e-06	0.000164	CbGpPWpGaD
Everolimus—MTOR—Disease—CDC42—epilepsy syndrome	6.57e-06	0.000164	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL18—epilepsy syndrome	6.51e-06	0.000162	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HSPB1—epilepsy syndrome	6.5e-06	0.000162	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CRH—epilepsy syndrome	6.5e-06	0.000162	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCL3—epilepsy syndrome	6.5e-06	0.000162	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CXCL2—epilepsy syndrome	6.5e-06	0.000162	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—OXT—epilepsy syndrome	6.5e-06	0.000162	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CERS1—epilepsy syndrome	6.48e-06	0.000161	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—L2HGDH—epilepsy syndrome	6.48e-06	0.000161	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—FAR1—epilepsy syndrome	6.48e-06	0.000161	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ADK—epilepsy syndrome	6.48e-06	0.000161	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GLUD1—epilepsy syndrome	6.48e-06	0.000161	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PDXK—epilepsy syndrome	6.48e-06	0.000161	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—RELA—epilepsy syndrome	6.46e-06	0.000161	CbGpPWpGaD
Everolimus—MTOR—Immune System—FYN—epilepsy syndrome	6.34e-06	0.000158	CbGpPWpGaD
Everolimus—MTOR—Immune System—MEF2C—epilepsy syndrome	6.3e-06	0.000157	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TSC2—epilepsy syndrome	6.26e-06	0.000156	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AGT—epilepsy syndrome	6.26e-06	0.000156	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—RELA—epilepsy syndrome	6.2e-06	0.000154	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—APOE—epilepsy syndrome	6.13e-06	0.000152	CbGpPWpGaD
Everolimus—MTOR—Immune System—YWHAZ—epilepsy syndrome	6.09e-06	0.000152	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MTOR—epilepsy syndrome	6.05e-06	0.000151	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PTK2B—epilepsy syndrome	6.05e-06	0.00015	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TSC1—epilepsy syndrome	6.05e-06	0.00015	CbGpPWpGaD
Everolimus—MTOR—Disease—HES1—epilepsy syndrome	6.02e-06	0.00015	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—KDR—epilepsy syndrome	6.01e-06	0.000149	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PTGS2—epilepsy syndrome	6e-06	0.000149	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PNPO—epilepsy syndrome	5.93e-06	0.000147	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NHLRC1—epilepsy syndrome	5.93e-06	0.000147	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—EPM2A—epilepsy syndrome	5.93e-06	0.000147	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GAMT—epilepsy syndrome	5.93e-06	0.000147	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCR2—epilepsy syndrome	5.88e-06	0.000146	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NTRK2—epilepsy syndrome	5.88e-06	0.000146	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SST—epilepsy syndrome	5.88e-06	0.000146	CbGpPWpGaD
Everolimus—MTOR—Disease—FYN—epilepsy syndrome	5.85e-06	0.000146	CbGpPWpGaD
Everolimus—MTOR—Disease—H2AFX—epilepsy syndrome	5.83e-06	0.000145	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—DUSP6—epilepsy syndrome	5.83e-06	0.000145	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PRKCB—epilepsy syndrome	5.78e-06	0.000144	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL6ST—epilepsy syndrome	5.76e-06	0.000143	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ADRA2A—epilepsy syndrome	5.76e-06	0.000143	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PLAT—epilepsy syndrome	5.73e-06	0.000143	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—JUN—epilepsy syndrome	5.66e-06	0.000141	CbGpPWpGaD
Everolimus—MTOR—Disease—YWHAZ—epilepsy syndrome	5.63e-06	0.00014	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CXCL12—epilepsy syndrome	5.53e-06	0.000138	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—BDKRB2—epilepsy syndrome	5.53e-06	0.000138	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—AKT1—epilepsy syndrome	5.53e-06	0.000137	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—QDPR—epilepsy syndrome	5.51e-06	0.000137	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CA4—epilepsy syndrome	5.51e-06	0.000137	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—POMC—epilepsy syndrome	5.49e-06	0.000137	CbGpPWpGaD
Everolimus—MTOR—Immune System—TSC2—epilepsy syndrome	5.45e-06	0.000136	CbGpPWpGaD
Everolimus—MTOR—Immune System—CRP—epilepsy syndrome	5.45e-06	0.000136	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—JUNB—epilepsy syndrome	5.43e-06	0.000135	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CNR1—epilepsy syndrome	5.43e-06	0.000135	CbGpPWpGaD
Everolimus—MTOR—Disease—CCR5—epilepsy syndrome	5.41e-06	0.000135	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PLCB1—epilepsy syndrome	5.41e-06	0.000134	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HTR7—epilepsy syndrome	5.29e-06	0.000132	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—POMC—epilepsy syndrome	5.27e-06	0.000131	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—COX3—epilepsy syndrome	5.18e-06	0.000129	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCL2—epilepsy syndrome	5.15e-06	0.000128	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HBEGF—epilepsy syndrome	5.14e-06	0.000128	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—SRC—epilepsy syndrome	5.07e-06	0.000126	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AKT3—epilepsy syndrome	5.05e-06	0.000125	CbGpPWpGaD
Everolimus—MTOR—Disease—TSC2—epilepsy syndrome	5.03e-06	0.000125	CbGpPWpGaD
Everolimus—MTOR—Immune System—PRKCB—epilepsy syndrome	5.03e-06	0.000125	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL6ST—epilepsy syndrome	5.01e-06	0.000125	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ADAM10—epilepsy syndrome	4.93e-06	0.000123	CbGpPWpGaD
Everolimus—MTOR—Disease—APOE—epilepsy syndrome	4.92e-06	0.000122	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—KCNB1—epilepsy syndrome	4.91e-06	0.000122	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CACNA2D2—epilepsy syndrome	4.91e-06	0.000122	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PFKL—epilepsy syndrome	4.91e-06	0.000122	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SLCO1A2—epilepsy syndrome	4.91e-06	0.000122	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SLC6A8—epilepsy syndrome	4.91e-06	0.000122	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—SRC—epilepsy syndrome	4.87e-06	0.000121	CbGpPWpGaD
Everolimus—FKBP1A—Disease—SRC—epilepsy syndrome	4.85e-06	0.000121	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—S100B—epilepsy syndrome	4.66e-06	0.000116	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—FGF2—epilepsy syndrome	4.66e-06	0.000116	CbGpPWpGaD
Everolimus—MTOR—Disease—IL6ST—epilepsy syndrome	4.62e-06	0.000115	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SOCS3—epilepsy syndrome	4.61e-06	0.000115	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CDC42—epilepsy syndrome	4.6e-06	0.000114	CbGpPWpGaD
Everolimus—MTOR—Immune System—FOS—epilepsy syndrome	4.59e-06	0.000114	CbGpPWpGaD
Everolimus—MTOR—Disease—NOS2—epilepsy syndrome	4.59e-06	0.000114	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—UPB1—epilepsy syndrome	4.49e-06	0.000112	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NEU1—epilepsy syndrome	4.49e-06	0.000112	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ATIC—epilepsy syndrome	4.49e-06	0.000112	CbGpPWpGaD
Everolimus—MTOR—Immune System—CASP8—epilepsy syndrome	4.48e-06	0.000111	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AVP—epilepsy syndrome	4.46e-06	0.000111	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HSD17B4—epilepsy syndrome	4.32e-06	0.000108	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—RELA—epilepsy syndrome	4.32e-06	0.000108	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MTOR—epilepsy syndrome	4.24e-06	0.000105	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HES1—epilepsy syndrome	4.21e-06	0.000105	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GBE1—epilepsy syndrome	4.18e-06	0.000104	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPP1R3C—epilepsy syndrome	4.18e-06	0.000104	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FYN—epilepsy syndrome	4.1e-06	0.000102	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—H2AFX—epilepsy syndrome	4.08e-06	0.000102	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MEF2C—epilepsy syndrome	4.08e-06	0.000101	CbGpPWpGaD
Everolimus—MTOR—Immune System—FGF2—epilepsy syndrome	4.05e-06	0.000101	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—YWHAZ—epilepsy syndrome	3.94e-06	9.8e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ASAH1—epilepsy syndrome	3.93e-06	9.77e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CASP3—epilepsy syndrome	3.9e-06	9.7e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NGF—epilepsy syndrome	3.9e-06	9.69e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—BCL2—epilepsy syndrome	3.85e-06	9.57e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—STXBP1—epilepsy syndrome	3.82e-06	9.5e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCR5—epilepsy syndrome	3.79e-06	9.43e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—JUN—epilepsy syndrome	3.79e-06	9.42e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—RELA—epilepsy syndrome	3.76e-06	9.35e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—FGF2—epilepsy syndrome	3.74e-06	9.3e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NT5E—epilepsy syndrome	3.72e-06	9.26e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALAD—epilepsy syndrome	3.72e-06	9.26e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HTR2A—epilepsy syndrome	3.71e-06	9.22e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MMP9—epilepsy syndrome	3.68e-06	9.16e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CACNA1A—epilepsy syndrome	3.55e-06	8.83e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALDH7A1—epilepsy syndrome	3.55e-06	8.83e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TSC2—epilepsy syndrome	3.52e-06	8.76e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AGT—epilepsy syndrome	3.52e-06	8.75e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ST3GAL3—epilepsy syndrome	3.48e-06	8.64e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—APOE—epilepsy syndrome	3.45e-06	8.57e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ADSL—epilepsy syndrome	3.4e-06	8.47e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL1B—epilepsy syndrome	3.4e-06	8.45e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SRC—epilepsy syndrome	3.4e-06	8.45e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KDR—epilepsy syndrome	3.38e-06	8.4e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PTGS2—epilepsy syndrome	3.37e-06	8.39e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GLUL—epilepsy syndrome	3.34e-06	8.3e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—VEGFA—epilepsy syndrome	3.31e-06	8.23e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—JUN—epilepsy syndrome	3.29e-06	8.19e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CACNA1D—epilepsy syndrome	3.28e-06	8.15e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PRKCB—epilepsy syndrome	3.25e-06	8.09e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL6ST—epilepsy syndrome	3.24e-06	8.05e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—AKT1—epilepsy syndrome	3.15e-06	7.84e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—TXNRD1—epilepsy syndrome	3.07e-06	7.62e-05	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—AKT1—epilepsy syndrome	3.03e-06	7.53e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—AKT1—epilepsy syndrome	3.01e-06	7.5e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AQP1—epilepsy syndrome	2.98e-06	7.4e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—POMC—epilepsy syndrome	2.96e-06	7.37e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—SRC—epilepsy syndrome	2.96e-06	7.35e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCL2—epilepsy syndrome	2.9e-06	7.21e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—SRC—epilepsy syndrome	2.73e-06	6.79e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CHRM3—epilepsy syndrome	2.69e-06	6.69e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—KCNJ11—epilepsy syndrome	2.69e-06	6.69e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FGF2—epilepsy syndrome	2.62e-06	6.51e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RELA—epilepsy syndrome	2.43e-06	6.05e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ABCG2—epilepsy syndrome	2.19e-06	5.46e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CASP3—epilepsy syndrome	2.19e-06	5.45e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP2C19—epilepsy syndrome	2.14e-06	5.32e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—JUN—epilepsy syndrome	2.13e-06	5.3e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP11A1—epilepsy syndrome	2.12e-06	5.28e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AKT1—epilepsy syndrome	2.11e-06	5.25e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MMP9—epilepsy syndrome	2.07e-06	5.15e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP2D6—epilepsy syndrome	1.92e-06	4.77e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SRC—epilepsy syndrome	1.91e-06	4.75e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—VEGFA—epilepsy syndrome	1.86e-06	4.63e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—AKT1—epilepsy syndrome	1.84e-06	4.57e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ADRA2A—epilepsy syndrome	1.83e-06	4.54e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—BCHE—epilepsy syndrome	1.82e-06	4.52e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SLC2A1—epilepsy syndrome	1.73e-06	4.31e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PLCB1—epilepsy syndrome	1.72e-06	4.27e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—TH—epilepsy syndrome	1.71e-06	4.25e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—AKT1—epilepsy syndrome	1.7e-06	4.22e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HMOX1—epilepsy syndrome	1.43e-06	3.55e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CAT—epilepsy syndrome	1.41e-06	3.5e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ABCB1—epilepsy syndrome	1.37e-06	3.41e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GPX1—epilepsy syndrome	1.27e-06	3.17e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AKT1—epilepsy syndrome	1.19e-06	2.95e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AGT—epilepsy syndrome	1.12e-06	2.78e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—APOE—epilepsy syndrome	1.09e-06	2.72e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—POMC—epilepsy syndrome	9.39e-07	2.34e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALB—epilepsy syndrome	8.57e-07	2.13e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTGS2—epilepsy syndrome	7.49e-07	1.86e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AKT1—epilepsy syndrome	3.77e-07	9.37e-06	CbGpPWpGaD
